Diamedica Therapeutics ( (DMAC) ) just unveiled an update.
DiaMedica Therapeutics announced updates to its ReMEDy2 trial for acute ischemic stroke, including expanding the patient pool and increasing interim analysis size, aimed at enhancing trial success and reducing costs. The company also reported regulatory approval for a Phase 2 trial of DM199 for preeclampsia in South Africa. Financially, DiaMedica has $50.2 million in cash and investments, with increased R&D expenses reflecting ongoing trial expansions.
Learn more about DMAC stock on TipRanks’ Stock Analysis page.
Trending Articles
- Paramount Global (NASDAQ:PARA) Gains From Yellowstone in Europe
- Ford (NYSE:F) Shares Slip After Huge New Fine
- Intel (NASDAQ:INTC) Notches Up Despite New Loss to AMD Processors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
